Delayed branching of endothelial capillary-like cords in glycated collagen I is mediated by early induction of PAI-1.

Development of micro- and macrovascular disease in diabetes mellitus (DM) warrants a thorough investigation into the repertoire of endothelial cell (EC) responses to diabetic environmental cues. Using human umbilical vein EC (HUVEC) cultured in three-dimensional (3-D) native collagen I (NC) or glycated collagen I (GC), we observed capillary cord formation that showed a significant reduction in branching when cells were cultured in GC. To gain insight into the molecular determinants of this phenomenon, HUVEC subjected to GC vs. NC were studied using a PCR-selected subtraction approach. Nine different genes were identified as up- or downregulated in response to GC; among those, plasminogen activator inhibitor-1 (PAI-1) mRNA was found to be upregulated by GC. Western blot analysis of HUVEC cultured on GC showed an increase in PAI-1 expression. The addition of a neutralizing anti-PAI-1 antibody to HUVEC cultured in GC restored the branching pattern of formed capillary cords. In contrast, supplementation of culture medium with the constitutively active PAI-1 reproduced defective branching patterns in HUVEC cultured in NC. Ex vivo capillary sprouting in GC was unaffected in PAI-1 knockout mice but was inhibited in wild-type mice. This difference persisted in diabetic mice. In conclusion, the PCR-selected subtraction technique identified PAI-1 as one of the genes characterizing an early response of HUVEC to the diabetic-like interstitial environment modeled by GC and responsible for the defective branching of endothelial cells. We propose that an upregulation of PAI-1 is causatively linked to the defective formation of capillary networks during wound healing and eventual vascular dropout characteristic of diabetic nephropathy.

[1]  L Orci,et al.  In vitro rapid organization of endothelial cells into capillary-like networks is promoted by collagen matrices , 1983, The Journal of cell biology.

[2]  D. Loskutoff,et al.  Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? , 1996, The Journal of cell biology.

[3]  R. Nicosia,et al.  The microvascular extracellular matrix. Developmental changes during angiogenesis in the aortic ring-plasma clot model. , 1987, The American journal of pathology.

[4]  Michael V. Doyle,et al.  Regulation of Integrin Function by the Urokinase Receptor , 1996, Science.

[5]  V. de Waard,et al.  Serial analysis of gene expression to assess the endothelial cell response to an atherogenic stimulus. , 1999, Gene.

[6]  Hiroshi Yamamoto,et al.  Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells , 1998, Diabetologia.

[7]  D. Lawrence,et al.  The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. , 1996, Nature.

[8]  N. Morisaki,et al.  Angiogenic effects of advanced glycation end products of the Maillard reaction on cultured human umbilical cord vein endothelial cells. , 1993, Biochemical and biophysical research communications.

[9]  T. Temelkova-Kurktschiev,et al.  Relationship between fasting plasma glucose, atherosclerosis risk factors and carotid intima media thickness in non-diabetic individuals , 1998, Diabetologia.

[10]  A. Schmidt,et al.  Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. , 1995, The Journal of clinical investigation.

[11]  R. Bucala,et al.  Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[12]  J. Norman,et al.  Hypoxia stimulates proximal tubular cell matrix production via a TGF-beta1-independent mechanism. , 1997, Kidney international.

[13]  P. Carmeliet,et al.  Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. , 1993, The Journal of clinical investigation.

[14]  J. Norman,et al.  Pexicrine effects of basement membrane components on paracrine signaling by renal tubular cells. , 1996, Kidney international.

[15]  M. Raftery,et al.  Number of interstitial capillary cross-sections assessed by monoclonal antibodies: relation to interstitial damage. , 1990, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[16]  T. Miyata,et al.  Autoxidation products of both carbohydrates and lipids are increased in uremic plasma: is there oxidative stress in uremia? , 1998, Kidney international.

[17]  M. Gerritsen,et al.  Altered proliferation of retinal microvascular cells on glycated matrix. , 1995, Investigative ophthalmology & visual science.

[18]  T. Lyons,et al.  Age-dependent accumulation of N epsilon-(carboxymethyl)lysine and N epsilon-(carboxymethyl)hydroxylysine in human skin collagen. , 1991, Biochemistry.

[19]  R. D. McCoy,et al.  Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. , 1996, Journal of Clinical Investigation.

[20]  S. Krungkrai,et al.  Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[21]  G. Laurent,et al.  * Author for correspondence Summary , 2022 .

[22]  C. Elmets,et al.  Relation between complications of type I diabetes mellitus and collagen-linked fluorescence. , 1986, The New England journal of medicine.

[23]  E. Cagliero,et al.  Increased Expression of Tissue Plasminogen Activator and Its Inhibitor and Reduced Fibrinolytic Potential of Human Endothelial Cells Cultured in Elevated Glucose , 1992, Diabetes.

[24]  R. Bucala,et al.  Immunochemical detection of advanced glycosylation end products in vivo. , 1992, The Journal of biological chemistry.

[25]  Ivar Giaever,et al.  Permissive Role of Nitric Oxide in Endothelin-induced Migration of Endothelial Cells* , 1997, The Journal of Biological Chemistry.

[26]  B. M. Mueller,et al.  The urokinase-type plasminogen activator receptor, a GPI-linked protein, is localized in caveolae , 1995, The Journal of cell biology.

[27]  M. Steffes,et al.  Renal interstitial expansion in insulin-dependent diabetes mellitus. , 1993, Kidney international.

[28]  S. Nigam,et al.  Transforming growth factor-beta selectively inhibits branching morphogenesis but not tubulogenesis. , 1997, The American journal of physiology.

[29]  H. Vlassara.  Recent Progress in Advanced Glycation End Products and Diabetic Complications , 1997, Diabetes.

[30]  A. Ljungqvist.  THE INTRARENAL ARTERIAL PATTERN IN THE NORMAL AND DISEASED HUMAN KIDNEY. A MICRO-ANGIOGRAPHIC AND HISTOLOGIC STUDY. , 1963, Acta medica Scandinavica.

[31]  W. Hörl,et al.  Endothelial cell adhesion molecule and PMNL response to inflammatory stimuli and AGE-modified fibronectin. , 1998, Kidney international.

[32]  A. Clowes,et al.  Plasminogen activator inhibitor type 1 and tissue inhibitor of metalloproteinases-2 increase after arterial injury in rats. , 1997, Circulation research.

[33]  S. Adler.  Structure-function relationships associated with extracellular matrix alterations in diabetic glomerulopathy. , 1994, Journal of the American Society of Nephrology : JASN.

[34]  Hiroshi Yamamoto,et al.  Advanced Glycation End Products-driven Angiogenesis in Vitro , 1997, The Journal of Biological Chemistry.

[35]  K. Preissner,et al.  Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. , 1997, Experimental cell research.

[36]  V. Monnier,et al.  Accelerated age-related browning of human collagen in diabetes mellitus. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[37]  D. Belin,et al.  The plasminogen activator/plasmin system. , 1991, The Journal of clinical investigation.

[38]  E. Tsilibary,et al.  Nonenzymatic glycosylation-induced modifications of intact bovine kidney tubular basement membrane. , 1993, The Journal of clinical investigation.

[39]  F. Martin,et al.  Suppression Subtractive Hybridization Identifies High Glucose Levels as a Stimulus for Expression of Connective Tissue Growth Factor and Other Genes in Human Mesangial Cells* , 1999, The Journal of Biological Chemistry.

[40]  F. Ziyadeh,et al.  Significance of tubulointerstitial changes in diabetic renal disease. , 1996, Kidney international. Supplement.

[41]  L. Lund,et al.  Impaired wound healing in mice with a disrupted plasminogen gene , 1996, Nature Medicine.

[42]  A. Cerami,et al.  Nonenzymatic glycosylation and the pathogenesis of diabetic complications. , 1984, Annals of internal medicine.

[43]  H. Schnaper,et al.  ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade. , 1995, Kidney international.

[44]  J. Malacara,et al.  Novel analytical approach to monitoring advanced glycosylation end products in human serum with on-line spectrophotometric and spectrofluorometric detection in a flow system. , 1997, Clinical chemistry.

[45]  L. Aiello,et al.  Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. , 1995, The Journal of clinical investigation.

[46]  V. Monnier,et al.  Longitudinal determination of skin collagen glycation and glycoxidation rates predicts early death in C57BL/6NNIA mice , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[47]  D. Belin,et al.  Plasminogen activator inhibitor-1 in acute hyperoxic mouse lung injury. , 1996, The Journal of clinical investigation.

[48]  E. Schleicher,et al.  Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. , 1997, The Journal of clinical investigation.

[49]  F. Gejyo,et al.  Polymorphisms of angiotensin converting enzyme and plasminogen activator inhibitor-1 genes in diabetes and macroangiopathy1. , 1998, Kidney international.

[50]  P. Carmeliet,et al.  Physiological consequences of loss of plasminogen activator gene function in mice , 1994, Nature.

[51]  L. V. Van Gaal,et al.  Elevated plasminogen activator inhibitor levels in cyclosporin-treated renal allograft recipients. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[52]  B. Tönshoff,et al.  Direct demonstration of insulin-like growth factor-I-induced nitric oxide production by endothelial cells. , 1994, Kidney international.

[53]  M. Brownlee,et al.  Glycosylation products as toxic mediators of diabetic complications. , 1991, Annual review of medicine.

[54]  N. Mackman,et al.  Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration. , 1996, The Journal of biological chemistry.

[55]  J. Sixma,et al.  Glycated proteins modulate tissue-plasminogen activator-catalyzed plasminogen activation. , 1997, Biochemical and biophysical research communications.